Literature DB >> 21620722

Moving to tolerance: clinical application of T regulatory cells.

Alicia N McMurchy1, Andrew Bushell, Megan K Levings, Kathryn J Wood.   

Abstract

Decreasing the incidence of chronic rejection and reducing the need for life-long immunosuppression remain important goals in clinical transplantation. In this article, we will review how regulatory T cells (Treg) came to be recognized as an attractive way to prevent or treat allograft rejection, the ways in which Treg can be manipulated or expanded in vivo, and the potential of in vitro expanded/generated Treg for cellular therapy. We will describe the first regulatory T cell therapies that have been or are in the process of being conducted in the clinic as well as the safety concerns of such therapies and how outcomes may be measured.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21620722      PMCID: PMC3836227          DOI: 10.1016/j.smim.2011.04.001

Source DB:  PubMed          Journal:  Semin Immunol        ISSN: 1044-5323            Impact factor:   11.130


  142 in total

1.  Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells.

Authors:  Qizhi Tang; Kammi J Henriksen; Elisa K Boden; Aaron J Tooley; Jianqin Ye; Sumit K Subudhi; Xin X Zheng; Terry B Strom; Jeffrey A Bluestone
Journal:  J Immunol       Date:  2003-10-01       Impact factor: 5.422

2.  Regulatory T cells, derived from naïve CD4+CD25- T cells by in vitro Foxp3 gene transfer, can induce transplantation tolerance.

Authors:  Jian-Guo Chai; Shao-An Xue; David Coe; Caroline Addey; Istvan Bartok; Diane Scott; Elizabeth Simpson; Hans J Stauss; Shohei Hori; Shimon Sakaguchi; Julian Dyson
Journal:  Transplantation       Date:  2005-05-27       Impact factor: 4.939

3.  Inducible reprogramming of human T cells into Treg cells by a conditionally active form of FOXP3.

Authors:  Sarah E Allan; George X Song-Zhao; Thomas Abraham; Alicia N McMurchy; Megan K Levings
Journal:  Eur J Immunol       Date:  2008-12       Impact factor: 5.532

4.  In vitro expanded human CD4+CD25+ regulatory T cells suppress effector T cell proliferation.

Authors:  K E Earle; Q Tang; X Zhou; W Liu; S Zhu; M L Bonyhadi; J A Bluestone
Journal:  Clin Immunol       Date:  2005-04       Impact factor: 3.969

5.  In vivo prevention of transplant arteriosclerosis by ex vivo-expanded human regulatory T cells.

Authors:  Satish N Nadig; Joanna Wieckiewicz; Douglas C Wu; Gregor Warnecke; Wei Zhang; Shiqiao Luo; Alexandru Schiopu; David P Taggart; Kathryn J Wood
Journal:  Nat Med       Date:  2010-05-16       Impact factor: 53.440

6.  Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection.

Authors:  Guillaume Oldenhove; Nicolas Bouladoux; Elizabeth A Wohlfert; Jason A Hall; David Chou; Liliane Dos Santos; Shaun O'Brien; Rebecca Blank; Erika Lamb; Sundar Natarajan; Robin Kastenmayer; Christopher Hunter; Michael E Grigg; Yasmine Belkaid
Journal:  Immunity       Date:  2009-11-05       Impact factor: 31.745

7.  GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells.

Authors:  Dat Q Tran; John Andersson; Rui Wang; Heather Ramsey; Derya Unutmaz; Ethan M Shevach
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-27       Impact factor: 11.205

8.  Ex vivo-expanded human regulatory T cells prevent the rejection of skin allografts in a humanized mouse model.

Authors:  Fadi Issa; Joanna Hester; Ryoichi Goto; Satish N Nadig; Tim E Goodacre; Kathryn Wood
Journal:  Transplantation       Date:  2010-12-27       Impact factor: 4.939

9.  Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. III. Further characterization of the CD4+ suppressor cell and its mechanisms of action.

Authors:  B M Hall; N W Pearce; K E Gurley; S E Dorsch
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

10.  Exogenous IFN-gamma ex vivo shapes the alloreactive T-cell repertoire by inhibition of Th17 responses and generation of functional Foxp3+ regulatory T cells.

Authors:  Gang Feng; Wenda Gao; Terry B Strom; Mohamed Oukka; Ross S Francis; Kathryn J Wood; Andrew Bushell
Journal:  Eur J Immunol       Date:  2008-09       Impact factor: 5.532

View more
  36 in total

Review 1.  Regulatory T-cell therapy for inflammatory bowel disease: more questions than answers.

Authors:  Megan E Himmel; Yu Yao; Paul C Orban; Theodore S Steiner; Megan K Levings
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

Review 2.  Regulatory immune cells in transplantation.

Authors:  Kathryn J Wood; Andrew Bushell; Joanna Hester
Journal:  Nat Rev Immunol       Date:  2012-05-25       Impact factor: 53.106

Review 3.  Bioprinting an Artificial Pancreas for Type 1 Diabetes.

Authors:  Juewan Kim; Kyungwon Kang; Christopher J Drogemuller; Gordon G Wallace; P Toby Coates
Journal:  Curr Diab Rep       Date:  2019-07-04       Impact factor: 4.810

4.  Obtaining regulatory T cells from uraemic patients awaiting kidney transplantation for use in clinical trials.

Authors:  D Berglund; M Karlsson; A-R Biglarnia; T Lorant; G Tufveson; O Korsgren; B Carlsson
Journal:  Clin Exp Immunol       Date:  2013-08       Impact factor: 4.330

Review 5.  Harnessing FOXP3+ regulatory T cells for transplantation tolerance.

Authors:  Herman Waldmann; Robert Hilbrands; Duncan Howie; Stephen Cobbold
Journal:  J Clin Invest       Date:  2014-04-01       Impact factor: 14.808

Review 6.  Cell therapy product administration and safety: data capture and analysis from the Production Assistance for Cellular Therapies (PACT) program.

Authors:  Robert W Lindblad; Laarni Ibenana; John E Wagner; David H McKenna; Derek J Hei; Peiman Hematti; Larry A Couture; Leslie E Silberstein; Myriam Armant; Cliona M Rooney; Adrian P Gee; Lisbeth A Welniak; Traci Heath Mondoro; Deborah A Wood; David Styers
Journal:  Transfusion       Date:  2014-10-14       Impact factor: 3.157

7.  Clinical grade isolation of regulatory T cells from G-CSF mobilized peripheral blood improves with initial depletion of monocytes.

Authors:  Pritesh Patel; Dolores Mahmud; Youngmin Park; Kazumi Yoshinaga; Nadim Mahmud; Damiano Rondelli
Journal:  Am J Blood Res       Date:  2015-12-25

8.  Combination peptide immunotherapy suppresses antibody and helper T-cell responses to the RhD protein in HLA-transgenic mice.

Authors:  Lindsay S Hall; Andrew M Hall; Wendy Pickford; Mark A Vickers; Stanislaw J Urbaniak; Robert N Barker
Journal:  Haematologica       Date:  2014-01-17       Impact factor: 9.941

9.  TNF-TNFR2 Signal Plays a Decisive Role in the Activation of CD4+Foxp3+ Regulatory T Cells: Implications in the Treatment of Autoimmune Diseases and Cancer.

Authors:  Md Sahidul Islam; Yang Yang; Xin Chen
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

10.  Sphingosine 1-Phosphate Receptor 3-Deficient Dendritic Cells Modulate Splenic Responses to Ischemia-Reperfusion Injury.

Authors:  Amandeep Bajwa; Liping Huang; Elvira Kurmaeva; Joseph C Gigliotti; Hong Ye; Jacqueline Miller; Diane L Rosin; Peter I Lobo; Mark D Okusa
Journal:  J Am Soc Nephrol       Date:  2015-08-18       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.